SAN FRANCISCO & MONTREAL--(BUSINESS WIRE)--Nomic Bio Inc. (Nomic), a proteomics company with the highest-throughput platform for multiplexed protein quantification, and the Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts, today announced a research collaboration to quantify circulating protein biomarkers that are associated with patient responses to immunotherapy across cancer types..

旧金山和蒙特利尔--（商业新闻短讯）--蛋白质组学公司Nomic Bio Inc.（Nomic），一家具有最高吞吐量的多重蛋白质定量平台，以及由世界领先的免疫肿瘤学专家组成的合作财团Parker癌症免疫治疗研究所（PICI），今天宣布了一项研究合作，以量化与患者对各种癌症类型免疫治疗反应相关的循环蛋白质生物标志物。。

Under the collaboration, Nomic will profile blood samples from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) cohort, a prospective longitudinal study of 1,070 patients receiving standard-of-care immune checkpoint inhibitor (ICI) treatment regimens in 52 community hospitals across the United States.

在这项合作下，OMIC将对PICI的RADIOHEAD（由协调分子数据集审问的免疫肿瘤患者的耐药驱动因素）队列的血液样本进行分析，这是一项前瞻性纵向研究，对1070名在美国52家社区医院接受标准护理免疫检查点抑制剂（ICI）治疗方案的患者进行了研究。

The testing, which will be conducted with Nomic’s nELISA platform, will provide parallel quantification of hundreds of proteins related to cancer and immune cell responses. The results will assess the levels of inflammatory and cancer-related proteins and explore their association with patient response to therapy, survival rates, and likelihood of developing immune-related adverse events..

这项测试将使用Nomic的nELISA平台进行，将对数百种与癌症和免疫细胞反应相关的蛋白质进行平行定量。结果将评估炎症和癌症相关蛋白的水平，并探讨它们与患者对治疗的反应，生存率以及发生免疫相关不良事件的可能性之间的关系。。

“By characterizing the soluble signaling molecules of our longitudinal patient samples, we aim to elucidate the communication pathways among immune cells in response to disease states and treatments,” said Tarak Mody, PhD, chief business officer at PICI. “The data from this mission-focused collaboration, along with other omics-data as part of the RADIOHEAD program, will enhance our understanding of treatment resistance and accelerate advancements in precision medicine to improve patient care.”.

PICI首席商务官塔拉克·莫迪（TarakMody）博士说：“通过表征纵向患者样本中的可溶性信号分子，我们旨在阐明免疫细胞之间对疾病状态和治疗的反应途径。”。。

This project will benefit from Nomic's revolutionary nELISA platform which provides industry-leading specificity and delivers absolute quantification of hundreds of key protein targets. These advancements combined with unparalleled throughput have already established Nomic as a leading proteomics solution provider in drug discovery..

该项目将受益于Nomic革命性的nELISA平台，该平台提供业界领先的特异性，并提供数百个关键蛋白质靶标的绝对定量。这些进步与无与伦比的吞吐量相结合，已经使Nomic成为药物发现领域领先的蛋白质组学解决方案提供商。。

“We are excited to work with PICI to help elucidate how cancer patients respond to immunotherapy, as it becomes a first-line treatment option across an increasing number of cancer types,” said Milad Dagher, CEO and Co-Founder of Nomic. “Since its inception, the raison d’être of Nomic has been to empower scientists with the data they need to improve patients’ lives.

“我们很高兴能与PICI合作，帮助阐明癌症患者对免疫疗法的反应，因为它已成为越来越多癌症类型的一线治疗选择，”National首席执行官兼联合创始人Milad Dagher说。“自成立以来，Nomic的存在理由一直是为科学家提供改善患者生活所需的数据。

This collaboration is a great opportunity for us to apply our nELISA technology to a project that can eventually help healthcare providers make more informed decisions about life-saving immunotherapies.”.

这一合作为我们将nELISA技术应用于一个项目提供了一个很好的机会，该项目最终可以帮助医疗保健提供者就挽救生命的免疫疗法做出更明智的决定。”。

Nomic and PICI intend to begin publishing data generated by the study in early 2025.

National和PICI打算在2025年初开始发布该研究产生的数据。

About Nomic

关于Nomic

At Nomic, we are making protein profiling broadly accessible. At the heart of our platform is the nELISA™, a proprietary technology that enables massive multiplexing with true flexibility, full quantification, and unmatched cost-efficiency. Nomic has developed the most comprehensive solution for inflammation research that allows for the high-throughput quantification of hundreds of secreted proteins.

在Nomic，我们正在使蛋白质分析广泛可用。我们平台的核心是nELISA™，这是一项专有技术，可实现大规模多路复用，具有真正的灵活性、全面量化和无与伦比的成本效益。Nomic为炎症研究开发了最全面的解决方案，可以对数百种分泌蛋白进行高通量定量。

Nomic is rapidly expanding its biological footprint to cover proteins across the entire proteome, unlocking new possibilities for diverse applications, uses cases, and disease areas. For more information, visit nomic.bio and follow the company on LinkedIn..

Nomic正在迅速扩大其生物足迹，以覆盖整个蛋白质组中的蛋白质，为不同的应用，用例和疾病领域开辟了新的可能性。有关更多信息，请访问nomic.bio并在LinkedIn上关注该公司。。

About the Parker Institute for Cancer Immunotherapy

关于帕克癌症免疫治疗研究所

The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, with an additional $125 million commitment announced in 2024, the San Francisco-based nonprofit is an unprecedented collaboration between the country’s leading immunotherapy researchers and cancer centers.

帕克癌症免疫治疗研究所（PICI）正在从根本上改变癌症研究的方式。这家总部位于旧金山的非营利组织成立于2016年，由硅谷企业家和慈善家肖恩·帕克（SeanParker）捐赠2.5亿美元，并于2024年宣布额外承诺1.25亿美元，是该国领先的免疫治疗研究人员和癌症中心之间前所未有的合作。

PICI Network research institutions include Stanford Medicine; the University of California, Los Angeles; the University of California, San Francisco; the University of Pennsylvania; Dana-Farber Cancer Institute; Gladstone Institutes; and Weill Cornell Medicine. PICI also supports top researchers at other institutions, including The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, City of Hope, Fred Hutchinson Cancer Research Center, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology and Washington University School of Medicine in St.

PICI网络研究机构包括斯坦福医学院；加利福尼亚大学洛杉矶分校；加利福尼亚大学旧金山分校；宾夕法尼亚大学；达纳·法伯癌症研究所；格莱斯顿研究所；和威尔·康奈尔医学。PICI还支持其他机构的顶尖研究人员，包括德克萨斯大学MD安德森癌症中心、纪念斯隆·凯特琳癌症中心、希望之城、弗雷德·哈钦森癌症研究中心、西奈山伊坎医学院、系统生物学研究所和圣路易斯华盛顿大学医学院。

Louis. By forging alliances with academic, industry and nonprofit partners, PICI makes big bets on bold research to fulfill its mission: to accelerate the development of breakthrough immunotherapies to turn all cancers into curable diseases. Find out more at parkerici.org and follow us on LinkedIn, X (formerly Twitter) @parkerici, and on Spotify and Apple Podcasts..

。通过与学术、工业和非营利合作伙伴结成联盟，PICI在大胆的研究上下了很大的赌注，以履行其使命：加速突破性免疫疗法的发展，将所有癌症转化为可治愈的疾病。请访问parkerici.org了解更多信息，并在LinkedIn、X（前Twitter）@parkerici、Spotify和苹果播客上关注我们。。

About RADIOHEAD

关于RADIOHEAD

The RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) program is a pan-tumor, prospective cohort study of 1000+ immunotherapy naive individuals on standard of care immune checkpoint inhibitor (CPI) treatment regimens. This study captured a comprehensive profile of each participant by collecting blood samples and clinical features at pretreatment, early on-treatment, and late timepoints from 52 community oncology clinics across the United States.

RADIOHEAD（由协调分子数据集审问的免疫肿瘤学患者的抗性驱动因素）计划是一项针对1000多名未接受免疫治疗的个体进行的标准护理免疫检查点抑制剂（CPI）治疗方案的泛肿瘤前瞻性队列研究。。

If participants experienced immune-related adverse events, additional samples were collected upon presentation and in follow-up visits. In all, over 3700 longitudinal samples were collected, with a focus on major IO indications such as non-small cell lung cancer (~1400 samples) and malignant melanoma (~500 samples).

如果参与者经历了与免疫相关的不良事件，则在介绍和随访时会收集额外的样本。总共收集了3700多个纵向样本，重点是主要的IO适应症，例如非小细胞肺癌（〜1400个样本）和恶性黑色素瘤（〜500个样本）。

Pairing comprehensive multi-omic profiling of these longitudinal samples with associated demographic and clinical outcomes provides an opportunity to identify clinically actionable mechanisms for CPI resistance and adverse events, discover targets for combination therapies and post-CPI treatment, and inform system biology approaches to elucidate disease pathways..

将这些纵向样本的综合多组学分析与相关的人口统计学和临床结果相结合，提供了一个机会，可以确定CPI耐药和不良事件的临床可行机制，发现联合治疗和CPI后治疗的目标，并为阐明疾病途径的系统生物学方法提供信息。。